Dermata Therapeutics Inc (DRMA) - Net Assets
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has net assets worth $3.96 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.07 Million) and total liabilities ($1.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Dermata Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.96 Million |
| % of Total Assets | 78.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 33.16 |
Dermata Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Dermata Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Dermata Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Dermata Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Dermata Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see Dermata Therapeutics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.56 Million | -75.44% |
| 2023-12-31 | $6.36 Million | +5.53% |
| 2022-12-31 | $6.02 Million | -40.42% |
| 2021-12-31 | $10.11 Million | +418.04% |
| 2020-12-31 | $-3.18 Million | -1412.16% |
| 2019-12-31 | $-210.16K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dermata Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4083207000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $252.00 | 0.02% |
| Other Components | $67.24 Million | 4306.99% |
| Total Equity | $1.56 Million | 100.00% |
Dermata Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Dermata Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alliance Pharma plc
LSE:APH
|
$4.26 Million |
|
Horus AG
STU:HRU
|
$4.26 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
$4.26 Million |
|
Vault Strategic Mining Corp.
V:KNOX
|
$4.27 Million |
|
Yunnan Water Investment Co. Limited
F:2WI
|
$4.25 Million |
|
Altur Slatina
RO:ALT
|
$4.25 Million |
|
PREMIER AFRICAN MINERALS
F:0PA
|
$4.24 Million |
|
Kuke Music Holding Ltd
NYSE:KUKE
|
$4.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dermata Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,355,018 to 1,561,094, a change of -4,793,924 (-75.4%).
- Net loss of 12,287,461 reduced equity.
- Share repurchases of 828 reduced equity.
- New share issuances of 6,886,102 increased equity.
- Other factors increased equity by 608,263.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.29 Million | -787.11% |
| Share Repurchases | $828.00 | -0.05% |
| Share Issuances | $6.89 Million | +441.11% |
| Other Changes | $608.26K | +38.96% |
| Total Change | $- | -75.44% |
Book Value vs Market Value Analysis
This analysis compares Dermata Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-60.56 | $1.33 | x |
| 2020-12-31 | $-915.83 | $1.33 | x |
| 2021-12-31 | $194.17 | $1.33 | x |
| 2022-12-31 | $87.19 | $1.33 | x |
| 2023-12-31 | $325.97 | $1.33 | x |
| 2024-12-31 | $10.20 | $1.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dermata Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -787.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.26x
- Recent ROE (-787.11%) is below the historical average (-191.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.92 Million |
| 2021 | -78.64% | 0.00% | 0.00x | 1.15x | $-8.96 Million |
| 2022 | -159.60% | 0.00% | 0.00x | 1.15x | $-10.21 Million |
| 2023 | -122.66% | 0.00% | 0.00x | 1.26x | $-8.43 Million |
| 2024 | -787.11% | 0.00% | 0.00x | 2.26x | $-12.44 Million |
Industry Comparison
This section compares Dermata Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dermata Therapeutics Inc (DRMA) | $3.96 Million | 0.00% | 0.28x | $4.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept… Read more